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a  b  s  t  r  a  c  t
The  promising  anticancer  properties  of  rodent  protoparvoviruses,  notably  H-1PV,  have  led to  their
clinical  testing.  This makes  it necessary  to  produce  highly  pure, well-characterized  virus  batches  in suf-
ﬁcient  quantity.  The  present  work  focused  on  developing  standardized  production,  puriﬁcation,  and
characterization  procedures  as a basis  for  exploiting  H-1PV  both  preclinically  and  in clinical  trials  for
anticancer  virotherapy.  Two  infection  and  two  virus  puriﬁcation  strategies  were  tested  and  the  result-
ing virus  preparations  compared  for their  purity  and  full-,  infectious-,  and  empty-particle  contents.  The
adopted  production  process,  which  involves  culturing  and infecting  NB-324K  cells  in 10-layer  CellSTACK®
chambers  (1  ×  103 infectious  units  per  infected  cell),  is  simple,  scalable,  and  reproducible.  Downstream
processing  to eliminate  contaminating  DNA  and  protein  includes  DNAse  treatment,  ﬁltration,  and  two
Iodixanol  density-gradient  centrifugations,  the ﬁrst gradient  being  a step  gradient  and  the  second,  either
10 11haracterization
apsid-ELISA
a  step  (1  ×  10 PFU/ml)  or a continuous  gradient  (3 × 10 PFU/ml).  A  procedure  was  also  developed  for
obtaining  infectious  particle-free  preparations  of  empty  virions  for  research  purposes:  cesium  chloride
density  gradient  centrifugation  followed  by UV  irradiation  (1 × 1014 physical  particles/ml).  For  quick,  sen-
sitive  determination  of physical  particles  (and  hence,  particle-to-infectivity  ratios),  a “Capsid-ELISA”  was
developed,  based  on  a novel  monoclonal  antibody  that  speciﬁcally  targets  assembled  capsids.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
H-1PV belongs to the genus Protoparvovirus within the Par-
ovirinae subfamily of Parvoviridae (Cotmore et al., 2014). It
onsists of a non-enveloped icosahedral capsid 25 nm in diame-
er and contains a single-stranded DNA genome about 5 kb long,
ncoding non-structural proteins – notably NS1 (83 kDa) and
S2 (25 kDa) – and the capsid proteins VP1 (81 kDa) and VP2
65 kDa). Another capsid protein, VP3 (63 kDa), is generated by
ost-translational cleavage of VP2 (Faisst et al., 1995; Halder et al.,
012; Hanson and Rhode, 1991; Toolan et al., 1960). Protopar-
oviruses replicate in an S-phase-dependent fashion and undergo
 lytic cycle after infection of permissive cells (Burnett et al., 2006).
hile the natural host of H-1PV is the rat, this virus has recently
Abbreviations: CPE, cytopathic effect; CS, CellSTACK®; CsCl, cesium chloride;
U, endotoxin unit; ELMI, electron microscopy; GP, genome containing viral parti-
le;  HAU, hemagglutination unit; HCP, host cell protein; IOD-PBS, Iodixanol-PBS;
U, infectious unit; MOI, multiplicity of infection; PFU, plaque forming unit; PP,
hysical particle; Q-PCR, quantitative real time PCR; RI, refraction index; RT, room
emperature; VIS-Ringer, Visipaque-Ringer.
∗ Corresponding author. Tel.: +49 6221424300.
E-mail address: B.Leuchs@dkfz.de (B. Leuchs).
ttp://dx.doi.org/10.1016/j.jviromet.2015.11.022
166-0934/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
raised much interest because it replicates preferentially in trans-
formed cells, including a number of human tumor cells. The virus
thus has oncolytic and oncosuppressive properties that have been
demonstrated in various cell cultures and animal models (Nuesch
et al., 2012; Rommelaere et al., 2010). In xenograft models, H-1PV
has been shown to suppress a number of human tumors, includ-
ing cervical tumors (Faisst et al., 1998; Li et al., 2013), pancreatic
tumors (Angelova et al., 2009b; Grekova et al., 2011), mammary car-
cinomas (Dupressoir et al., 1989), gliomas (Geletneky et al., 2010;
Kiprianova et al., 2011), and lymphomas (Angelova et al., 2009a).
On the basis of these preclinical proofs of concept, a ﬁrst clini-
cal trial (phase I/IIa) of H-1PV ParvOryx01 (clinical trial identiﬁer
NCT01301430) was launched in 2011 in patients with recurrent
glioblastoma multiforme (Geletneky et al., 2012),
To test and eventually exploit the therapeutic potential of H-
1PV, it is necessary to develop an efﬁcient, simple, and reproducible
virus production process and reliable assays for the quantitative
and qualitative characterization of ﬁnal virus batches. Meth-
ods have been published for small-scale production of H-1PV in
NB-324K cells and its puriﬁcation by cesium chloride (Halder
et al., 2012; Paradiso, 1981) or Iodixanol (Wrzesinski et al., 2003;
Zolotukhin et al., 1999) density gradient centrifugation. The liter-
ature also describes titration of infectious virions by plaque assay
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Tattersall and Bratton, 1983), of H-1PV physical particles by elec-
ron microscopy (Halder et al., 2012) or hemagglutination assay
Kongsvik and Toolan, 1972), and of genome-containing particles
y quantitative PCR (Lacroix et al., 2010). However, no system-
tic, comparative analyses have been conducted to determine and
ptimize virus yield and purity or the sensitivity of analytical meth-
ds for virus quantiﬁcation and quality monitoring. The aims of
he present study were thus to standardize and optimize H-1PV
roduction, puriﬁcation, and characterization. This has led us to
ntroduce major innovations for large-scale virus production, with
limination of unwanted contaminants through improved virus
atch clariﬁcation and infectious particle puriﬁcation. We  have
lso focused on obtaining infectious-virion-free empty-particle
atches for use as non-infectious controls in preclinical studies.
o detect assembled viral capsids, we have developed a quick,
onvenient ELISA exploiting an in-house-generated monoclonal
ntibody (BL-H1) that might further be used for basic investigation
f protoparvovirus assembly and to monitor viremia and serocon-
ersion in virus-treated patients. Altogether, these standardization
nd development efforts have yielded reliable up- and downstream
rocesses for the reproducible and efﬁcient preparation of H-1PV
tocks meeting the quantity and quality requirements for clinical-
rade virus batches.
. Materials and methods
.1. Producer cell line, H-1PV virus stock
NB-324K human newborn kidney cells transformed with simian
irus 40 (SV40) (Tattersall and Bratton, 1983) were cultured at 37 ◦C
n minimum essential medium (MEM,  Sigma, Germany) with 5%
eat-inactivated fetal bovine serum (FBS, Biowest, France) in a 5%
O2 atmosphere. The medium was supplemented with 100 U/ml
enicillin, 100 g/ml streptomycin, and 2 mM L-glutamine (Life
echnologies, Germany). For production, NB-324K cells propagated
n 175-cm2 Y-ﬂasks (Nunc, Denmark) were seeded into a 10-layer
ellSTACK® culture chamber (Corning, Germany) with a 6360 cm2
rowth area. Cell density and viability were measured by staining
iving cells with 0.4% trypan blue (InvitrogenTM, Germany). Cells
ere counted with a Countess® Cell counter (Life Technologies,
ermany). An in-house puriﬁed H-1PV virus stock was  used to
nfect the cells.
.2. H-1PV production
A 10-layer CellSTACK® (CS) was chosen as a convenient single-
se production system. For simultaneous cell seeding and infection,
B-324K cells were seeded at 3.6 × 104 cells/cm2 into the 10-layer
S and infected immediately with H-1PV at a multiplicity of infec-
ion (MOI) of 0.01 plaque forming units (PFU) per cell. The pH during
nfection was 7.0 ± 0.1. The infected cells were incubated for 4 days
t 37 ◦C under 5% CO2 until the cytopathic effect (CPE), measured
s the percentage of dead and detached cells observed under a
icroscope, reached at least 30%. For non-simultaneous seeding
nd infection, NB-324K cells were seeded at 7.9 × 103 cells/cm2 into
 10-layer CS and allowed to grow for three days, by which time
hey had reached a density of approximately 3.6 × 104 cells/cm2,
s measured on a control-ﬂask culture. These anchored cells were
hen infected at a MOI  of 0.01 PFU/cell and incubated for 4 days as
escribed above. For harvesting, the medium was  aspirated and
nfected cells were treated with PBS/1 mM EDTA. The medium
upernatant and detached cells were centrifuged for 5 min  at
000 × g. The pellet was washed with PBS, resuspended in Virus
ris/EDTA lysis buffer, pH 8.7 (VTE) containing 0.05 M Tris–HCl,
.5 mM  EDTA, and subjected to three freeze–thaw cycles. After cen-
rifugation for 5 min  at 5000 × g, cell debris were discarded. The celll Methods 229 (2016) 48–59 49
lysate was  then sonicated at 48 W for 1 min  in a Sonorex Super 10
P ultrasonic homogenizer (Bandelin, Germany) and treated with
DNAse (50 U/ml, Sigma, Germany) for 30 min  at 37 ◦C to eliminate
the non-encapsidated viral DNA and contaminating host cell DNA.
2.3. H-1PV puriﬁcation
The DNase-treated virus harvest was  clariﬁed by ﬁltration
through a 0.2-m Sartolab® P20 Plus ﬁlter (Sartorius, Germany).
Two different methods were used to purify the virus, either two
consecutive Iodixanol gradients or a cesium chloride density gra-
dient followed by dialysis against VTE buffer. The consecutive
Iodixanol gradients consisted of a ﬁrst step gradient of Iodixanol-
PBS (IOD-PBS) followed by either a step or a continuous gradient of
Visipaque-Ringer (VIS-Ringer).
2.3.1. IOD-PBS and VIS-Ringer density step gradients
To eliminate proteins, a step density gradient centrifugation
was done as described by Zolotukhin (Zolotukhin et al., 1999). For
this, 25 × 89 mm Quickseal tubes (Beckmann, Germany) were ﬁlled
with 20 ml  virus suspension. This suspension was  underlaid with
four layers of Iodixanol (Axis-Shield, Norway) in PBS (Iodixanol
concentrations: 15%, 25%, 40%, and 60%). Ultracentrifugation was
performed for 2 h at 4 ◦C in a 50.2 Ti rotor at 50,000 rpm (Beckmann,
L870 M,  Germany). Usually, 3.5 ml  virus suspension was collected
from the 40% Iodixanol layer. Afterwards, a second density gradi-
ent centrifugation was performed with Visipaque (GE Healthcare,
Norway) diluted in Ringer solution (B. Braun, Germany) for further
protein elimination and separation of full from empty particles.
For this, 25 × 89 mm Quickseal tubes were ﬁlled with virus sus-
pension from the IOD-PBS density gradient, diluted at least 1:2.5
in Ringer solution. Then 5 ml  of 25%, 4 ml  of 40%, and 4 ml  of 55%
Visipaque in Ringer solution were underlaid. For detection of the
40% layer, a reference gradient was  made, where the 25% and 55%
Visipaque/Ringer phases were colored with phenol red. Addition-
ally, the location of the 40% phase was marked on the outside of the
sample tube. Ultracentrifugation was performed for 2 h at 4 ◦C in a
50.2 Ti rotor at 50,000 rpm. After centrifugation two fractions were
collected in the region of the original 40% phase using a syringe and
hollow needle: a 2.5 ml  lower band and a 800 l upper band cor-
responding to the full and empty-particle fractions. The refraction
index of a 5 l sample was measured with a refractometer (AR200,
Reichert Analytical Instruments, Germany) and the densities of the
regions from which the fractions were taken were calculated using
a reference table for Iodixanol (Axis-Shield, Norway).
2.3.2. Continuous VIS-Ringer gradient
For the continuous VIS-Ringer gradient, Quickseal tubes were
ﬁlled with virus suspension diluted in Ringer solution to a refrac-
tion index of 1.3815 (corresponding to 30% Visipaque). The virus
suspension was underlaid with 0.5 ml  of 65.2% Visipaque cushion,
and the tube was  completely ﬁlled with 30% Visipaque/Ringer solu-
tion. Ultracentrifugation was performed for 10 h at 4 ◦C in a 70.1 Ti
rotor at 63,000 rpm. Fractions of about 500 l were collected from
the bottom under controlled dripping.
2.3.3. Cesium chloride density gradient and dialysis
A CsCl density gradient was established as described previously
(Paradiso, 1981). For this, 14 × 95 mm polyallomere centrifuge
tubes (Beckmann, Germany) were ﬁlled with 5 ml CsCl at 1.4 g/cm3
density and overlaid with 1 ml  1 M saccharose followed by 5 ml
virus suspension. Ultracentrifugation was performed at 15 ◦C for at
least 20 h at 39,000 rpm in an SW41 rotor. Different fractions were
collected from the bottom (fr# 1: 500 l, fr# 2: 300 l, fr# 3–20:
200 l) and the capsid (physical particle, PP) content was  measured
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y means of a new ELISA (H-1PV Capsid-ELISA) or by hemagglu-
ination assay (see Section 2.6 below). Both methods allow the
uantiﬁcation of all viral particles irrespective of their infectiv-
ty. The refraction index was measured and the density calculated
ccording to a reference table for CsCl (Grifﬁth, 2006). Fractions
ontaining full or empty capsids were pooled and directly dialyzed
gainst 1000 volumes of VTE buffer for approximately 30 min  at
oom temperature. This was followed by three dialysis cycles at
◦C to eliminate the toxic CsCl.
.4. UV inactivation of the empty-particle pool
For inactivation of residual infectious particles in the empty-
article pool, 500 l of empty-particle fraction was placed at the
enter of a 6-cm dish (Greiner Bio-One, Germany) under a sterile
aminar ﬂow hood. A UV lamp (Type NU-4, Herolab, Germany) emit-
ing at 254 nm was used to irradiate the sample at 0.5 mW/cm2, as
easured with a radiometer (VLX-3W, Benda, Germany). The sam-
le was irradiated 4 times for 2 min  with intervals of 5 min  without
V.
.5. Development and characterization of the monoclonal
ntibody BL-H-1
To generate a monoclonal antibody against H-1PV capsids (PP),
alb/c mice (Charles River, Germany) were immunized intraperi-
oneally, 3 times over a 3-month period, with 1.2 × 108 PFU each
ime. One week after the last H-1PV injection, their spleens were
emoved and spleen cells were fused with X63/Ag8 lymphoma
ells (Kuck et al., 2007; Wobus et al., 2000). The hybridoma cells
ere propagated and the undiluted supernatants (40 l) from sin-
le clones were screened by Western dot blotting against puriﬁed
-1PV. Positive wells were selected by single-colony analysis, and
fter three selection rounds, the selected hybridoma cells were used
o produce BL-H1 antibodies in a CELLine 1000 bioreactor (Integra
iosciences AG, Switzerland).
RPMI 1640 medium supplemented with 10% FBS, 100 g/ml
enicillin, 100 g/ml streptomycin, 2 mM L-glutamine, 20 mM
EPES pH 7.2 was used to culture the hybridoma cells. The
ubclass of the BL-H1 antibody was determined with the Amer-
ham mouse monoclonal antibody isotyping kit (Braunschweig,
ermany). Puriﬁcation was done with the HiTrapTM Protein A
P afﬁnity column kit (GE Healthcare, Sweden) and the Äkta
rime system (GE Healthcare, Germany). The IgG2a concentration
as determined with the Mouse IgG2a ELISA Set (BD Biosciences,
ermany).
.6. Virus quantiﬁcation and characterization
.6.1. Sucrose density gradient fractionation of assembled and
on-assembled viral capsid proteins
Extract was prepared from 293T cells (CRL-11268, American
issue Culture Collection) transfected with an infectious H-1PV
olecular clone (Kestler et al., 1999) and harvested 72 h post-
ransfection. One milliliter of extract was transferred to a 10–50%
inear sucrose gradient. Centrifugation was performed at 4 ◦C for
.3 h at 28,000 rpm in a TST 41.14 (Kontron) rotor. Fractions (400 l)
ere collected and analyzed by Western blotting, hemagglutina-
ion, infectivity and genome-containing particles titration assays
see below).
.6.2. H-1PV detection through native Western dot blotting
Sucrose density gradient fractions (diluted 1:10 in 100 l
BS) were transferred to a nitrocellulose membrane (AppliChem,
ermany) with a vacuum blotter. Washing steps were carried out
ith PBS, 0.05% Tween 20. The membrane was blocked for 1 h withl Methods 229 (2016) 48–59
PBS containing 5% skimmed milk powder and incubated with either
puriﬁed mAb  BL-H1 (1:1000) or VP antibody (1:500 diluted). The
membrane was then washed for 30 min  at RT and incubated with
secondary peroxidase-coupled goat anti-mouse (GE Healthcare,
Germany) or goat anti-rabbit antibody (GE Healthcare, Germany)
in PBS. Detection was done with ECL Plus and Hyperﬁlm ECL (Amer-
sham Biosciences GmbH, Germany).
2.6.3. Plaque formation assay
Plaque assays were done essentially as described by Tattersall
and Bratton (1983). NB-324K cells were grown in monolayer
cultures in MEM  medium containing 5% FBS, 100 g/ml peni-
cillin, 100 g/ml streptomycin, and 2 mM L-glutamine. They were
infected at 60% conﬂuence with serial dilutions of H-1PV and
incubated for 1 h at 37 ◦C. Then the inoculum was replaced with
a bacto-agar overlay (1.7% in MEM  containing 5% FBS). On day
four post-infection, living cells were stained for 18–24 h by addi-
tion of 0.02% toluylene red staining solution (Sigma, Germany)
containing bacto-agar (Becton Dickinson, Germany). The dishes
were incubated at 37 ◦C under 5% CO2. Plaque-forming units were
counted 5 days post-infection on a light box and their concentration
expressed in PFU/ml.
2.6.4. DNA hybridization assay for infectious H-1PV
NB-324K cells (7.6 × 103 cells/well) were seeded into a 96-well
Plate 24 h prior to infection with H-1PV. They were infected with
10-fold serial dilutions of H-1PV and incubated for 72 h at 37 ◦C
under 5% CO2. The infected cells were lysed in the plates by
freezing at −80 ◦C and thawing, followed by alkaline treatment
(1.5 M NaOH). The cell lysate including viral DNA was  transferred
to a nylon membrane, cross-linked with a CL-1000 Ultraviolet
Crosslinker (UVP, USA), and hybridized with an NS1-speciﬁc 32P-
radiolabeled probe prior to autoradiography. Virus titration was
performed in duplicate and the titer expressed in infectious units
(IU) per ml (Lacroix et al., 2010).
2.6.5. Determination of genome-containing viral particles
The number of genome-containing viral particles (GP) was
determined by Q-PCR, essentially as described previously (Lacroix
et al., 2010). Each well received 20 l reaction mix containing 1x
Premix Ex TaqTM (TaKaRa, France), 0.3 M labeled NS1-TaqManTM
probe, each primer at 0.3 M,  and 3 l template. Q-PCR was run
in an Abi Prism 7900 HT Sequence Detection System and results
were processed with the SDS 2.1 software (Applied Biosystems,
Germany).
2.6.6. Hemagglutination assay
For the measurement of hemagglutination units (Kongsvik and
Toolan, 1972), the CsCl density gradient fractions were diluted 1:25
in PBS and further diluted serially 1:2 in a round-bottom 96-well
plate (Greiner Bio-One, Germany). Next, 25 l of a 2% suspension
of guinea pig red cells (Charles River Laboratories, Germany) in PBS
was added. The plate was  incubated for 1 h at 4 ◦C and the titer read
as the highest dilution at which hemagglutination was complete.
2.6.7. H-1PV capsid-ELISA
An ELISA was  developed for detection of capsids (full or empty,
henceforth called “physical particles” or PP). A ﬂexible 96-well, U-
bottomed plate (BD Falcon, NJ) was  coated overnight at 4 ◦C with
100 l monoclonal antibody BL-H1 at 2 ng/l in PBS. The gener-
ation of this antibody, which has been patented (Leuchs et al.,
2010), is described in above Section 2.5. The coating solution was
removed, 200 l blocking buffer (2 mg/ml  casein (Sigma, Germany)
and 0.05% Tween 20 (Sigma, Germany) in PBS) was  added to each
well, and the mixture incubated for 1 h at 37 ◦C. Blocking buffer
was aspirated and the wells were washed with PBS, 0.05% Tween
ologica
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0, after which the positive control, the negative control, the sam-
le, and serial dilutions of H-1PV standard (all of them in PBS
uffer) were plated in duplicate at 100 l/well. The plate was incu-
ated for 1 h at 37 ◦C. The reaction mixture was aspirated and
he wells were washed. Next, 100 l mAb  BL-H1 labeled with
orseradish peroxidase (0.1 g/ml) was added to each well and
ncubated for 1 h at 37 ◦C. Samples were aspirated and the wells
ere washed with PBS, 0.05% Tween 20. After addition of 100 l
,3′,5,5′-tetramethylbenzidine (Sigma, Germany) to each well, the
late was incubated for 15 min  at room temperature in the dark. The
eaction was stopped by adding 100 l of 1 M H2SO4 per well. Sam-
le absorbance was measured at 450 nm with an Ascent Multiscan
late Reader (Thermo Fisher Scientiﬁc, Germany).
To standardize the ELISA, H-1PV samples containing known
mounts of particles were prepared. The H-1PV PP titers of these
tandard were determined by mixing an aliquot with appropri-
te dilutions of a stock of adenovirus type 5 (Ad5, American Type
ulture Collection) of known titer, and visualizing the mixture by
lectron microscopy (see below). On 8 randomly chosen pictures,
-1PV and Ad5 particles were counted and the titer of H-1PV par-
icles was determined in relation to the known Ad5 titer.
.6.8. Bicinchoninic acid (BCA) and Bradford assays
Protein concentration was determined by colorimetric assays.
n the protein concentration range between 5 and 250 g/ml the
ierce® BCA Protein Assay Kit 23227 (Pierce, USA) was  used.
he protein concentration was measured against a bovine serum
lbumin (BSA) standard at 562 nm using a Nanodrop 2000 spec-
rophotometer. In the 50–2000 g/ml range, protein concentration
as measured at 595 nm,  using the Bradford assay performed in a
6-well plates with BSA as a standard (Sigma, Germany).
.6.9. SDS-PAGE, silver staining, and Western blotting
To assess the purity of virus preparations, a 10% SDS-PAGE was
erformed (SERVA Electrophoresis, Germany), followed by silver
taining (Invitrogen, CA) and Western blotting. For viral capsid
rotein (VP) detection, polyclonal rabbit anti-VP (VP) (provided
y C. Dinsart, DKFZ, Heidelberg) and a horseradish-peroxidase-
onjugated anti-rabbit IgG (AmershamTM ECL Western Blotting
nalysis) were used.
.6.10. DNA measurement
DNA was quantiﬁed by measuring the absorbance at 260 nm
ith a Nanodrop spectrophotometer. Human genomic DNA in the
irus preparations was quantiﬁed by Q-PCR with the Quantiﬁler®
uman DNA Quantiﬁcation Kit (Applied Biosystems, Germany)
or detection of h-TERT (human telomerase reverse transcriptase),
ccording to the manufacturer’s instructions. The detection limit
as 26 ng/ml and the amplicon size was 62 bp. As positive control,
B-324K cell genomic DNA was used.
.6.11. Endotoxins and sterility
Contamination by endotoxins was tested with the Endosafe®
el-Clot Limulus Amebocyte Lysate Assay (Charles River Laborato-
ies, Germany). Thereby 100 l of sample were added to 100 l of
imulus amebocyte lysate and the mixture was incubated at 37 ◦C
or 1 h. The presence of endotoxins is revealed through the activa-
ion of a coagulation cascade resulting in a gel clot. The sensitivity
f the assay was 0.25 endotoxin unit (EU) per milliliter. Each H-
PV preparation was also checked for the absence of bacterial or
ungal contamination by incubating 2.5 l of the preparation on
oy/peptone-agar for 5 days at 37 ◦C and testing for colony forma-
ion.l Methods 229 (2016) 48–59 51
2.6.12. Electron microscopy
For qualitative analysis of virus preparations, electron
microscopy pictures were taken. For this, 5 l virus suspen-
sion was added to a ready-to-use carbon-coated copper grid and
incubated for 2 min. The grid was then washed with 5 l Bidest
water and coated with 2% uranyl acetate for 30 s. The drops were
absorbed from the grid with Whatman 50 ﬁlter paper and the grid
was dried for approximately 1 min. Photos were taken at a 20,100×
magniﬁcation using a Zeiss transmission electron microscope at
an operating voltage of 80 kV.
3. Results
The aim of this study was to standardize the H-1PV manufac-
turing procedure. This involved characterizing each upstream and
downstream process step, ensuring reproducibility, and fully char-
acterizing the identity, purity, and safety of the ﬁnal product in
order to establish standard operating procedures.
Two  alternative methods of cell preparation and infection were
tested upstream from the core production process. We  also com-
pared two  different puriﬁcation tracks downstream from core
production. A ﬂow chart of the overall process is given in Fig. 1.
Table 1 summarizes the assays used to characterize intermedi-
ate steps in the production procedure and the ﬁnal product as
described below. To quantify physical particles more conveniently,
it was necessary to establish a new assay, described in Sections 3.1
and 3.2.
3.1. Characterization of BL-H1, a novel capsid-speciﬁc
monoclonal antibody
Two  goals of this study were to separate full from empty
particles and to determine the particle-to-infectivity ratio of the
ﬁnal product. Determining this ratio, which should inﬂuence both
the therapeutic efﬁcacy of parvoviral treatment and the expected
immune response, requires determining the total number of phys-
ical particles (PP). To develop a convenient method for quantifying
PP, we  generated a monoclonal antibody against H-1PV, which rec-
ognizes native capsids but fails to recognize non-assembled capsid
proteins or denatured capsids. This antibody, called BL-H1, is of type
IgG2a. Its speciﬁcity is illustrated in Fig. 2, which shows the results of
various analyses performed on the fractions obtained after sucrose
density centrifugation of extracts of 293T cells transfected with
an infectious H-1PV molecular clone. On Western dot blots, the
only fractions giving a signal with both VP antiserum (predomi-
nantly recognizing non-assembled capsid proteins) and mAb  BL-H1
were fractions 9–18. These fractions were found to contain assem-
bled capsids, as demonstrated by measuring hemagglutination,
GPs and IU. BL-H1 did not react with fractions 3–8, containing
non-assembled or partially assembled capsid proteins. Fractions
9–19 included both empty and genome-containing particles, with
infectious particles concentrating in fractions 12–19. Interestingly,
although the hemagglutination and BL-H1 signals were conﬁned
to the same region of the gradients, the latter peak was shifted
towards higher densities. Furthermore, BL-H1 was  found not to
react with denatured capsid proteins and showed no cross-reaction
with capsids of the closely related protoparvovirus minute virus of
mice (data not shown).
3.2. ELISA for H-1PV capsid quantiﬁcation
To quantify physical particles throughout H-1PV production,
we developed a “Capsid-ELISA” using mAb  BL-H1. The ELISA
showed a reproducible linear relationship between the number
of PP (in the range 2.5 × 109 to 3.9 × 107 PP) and absorbance at
450 nm (Fig. 3). Two  of the tested dilutions, QC-L (low virion load)
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Fig. 1. Flow diagram of H-1PV production with the recommended procedures for preparing infectious (A) and empty (B) particles.
Table 1
Assays used for the quantitative and qualitative characterization of H-1PV stocks.
Assay Type of characterization Unit
Plaque formation assay Biological assay for virus multiplication and spread. Virus titers expressed in plaque
forming units
PFU/ml
DNA hybridization assay for infectivity In situ assay for virus infection and DNA replication. Virus titers expressed in
infectious units
IU/ml
Viral genome quantiﬁcation by real-time PCR
(Q-PCR)
Physical characterization for presence of genome containing viral particles GP/ml
Capsid-ELISA Physical determination of assembled viral particles, expressed in physical particles. PP/ml
Hemagglutination assay Physical characterization for virus mediated guinea pig erythrocytes agglutination.
Virus titer expressed in hemagglutination units.
HAU/ml
Refraction index measurement Physical determination of density from the refractive index (RI) mg/cm3
Bicinchoninic and Bradford assays Colorimetric protein quantiﬁcation g protein/ml
SDS-PAGE and Western blot Determination of purity and identity of viral proteins –
Q-PCR with h-TERT quantiﬁler Quantiﬁcation of cell genomic DNA ng DNA/ml
A260 measurement Spectrometric determination of DNA ng DNA/ml
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(Electron  microscopy Ultrastructural visualiz
LAL  assay Determination of endo
Sterility assay Determination of bacte
nd QC-M (medium virion load) were used as quality controls in
ubsequent assays. When CsCl density gradient centrifugation was
sed to separate empty from full H-1PV capsids, this ELISA allowed
uantiﬁcation of both. This is illustrated in Fig. 4, showing the
istribution of capsids (as determined by our Capsid-ELISA and by
emagglutination assay) and that of genome-containing particles
fter centrifugation. The two methods for detecting physical
articles gave superimposable proﬁles, with a major peak for
mpty capsids and two minor ones for full capsids. PCR detection
f DNA-containing capsids likewise revealed two  density groups
fractions 4–6 and fractions 7–10). While the intermediate densityof virus stocks –
nits EU/ml
d fungi colony-forming units on soy/peptone-agar plates CFU/ml
particles may  consist of defective interfering particles (Faust and
Ward, 1979), their nature was  not analyzed further. Nevertheless,
our results clearly show that the developed ELISA is suitable for
routine detection of physical particles.
3.3. Large-scale production of H-1PV3.3.1. Optimization of cell seeding and infection
We ﬁrst optimized the cell density at the time of infection, the
MOI, and the time of harvest. The highest virus yields were obtained
with a cell density of 3.6 × 104 cells/cm2, a MOI  of 1 × 10−2 PFU/cell,
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iig. 2. Characterization of antibodies targeting viral capsid proteins. Protein extra
ere  analyzed by sucrose gradient centrifugation. Individual fractions were analyz
ative Western dot blotting with BL-H1 or VP antibodies. The data show that BL-H
nd harvesting 4 days post-infection, with approximately 30% CPE
data not shown). These conditions were used subsequently in all
roduction experiments, the only difference being that some cells
ere grown in 175-cm2 Y-ﬂasks, harvested, transferred to a CS, and
nfected immediately, while others were allowed to grow in the CS
or three days prior to infection.
Table 2a shows that cells infected and seeded simultaneously
nd cells allowed to grow for three days in the CS prior to infection
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ndicated as “QC-L” and “QC-M” contained, respectively, 4 and 8 × 108 particles and werepared from 293T HEK cells transfected with an infectious H-1PV molecular clone
 the presence of GP, IU, HAU, and VP proteins. VPs were detected, respectively, by
b speciﬁcally recognizes assembled capsids, while VP recognizes VP proteins.
did not differ signiﬁcantly as regards either virus production per
infected cell or virus release into the supernatant per infected
cell. In both cases, approximately 1 × 103 PFU were produced per
infected cell, corresponding to an average yield of 2 × 1011 PFU per
10-layer CellSTACK®. Protein concentrations in the virus harvests
obtained were also similar for the two procedures (2 × 103g/ml),
indicating that the two cultures reached the same density at
harvest time. As infection three days post-seeding saved working
y = 1E-09x  - 0.0912
+09 2.0E+ 09 2. 5E+ 09 3.0E+ 09
articles
ersus the number of H-1PV particles added (as determined by ELMI). The indicated
inear dose–response was derived from the regression analysis of data. The samples
 used subsequently as low- and medium-concentration quality control standards.
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Table 2a
Infectious-particle recoveries after two different seeding/infection procedures.
Seeding/infection procedure PFU/infected cell g/ml protein
Cell extract
3 days in CS prior to infection 1.1 ± 1.8E + 03 2.0 ± 0.9E + 03
Simultaneous seeding and infection 0.8 ± 0.4E + 03 1.7 ± 0.4E + 03
Medium supernatant
3 days in CS prior to infection 0.1 ± 0.2E + 03 0.8 ± 0.4E + 03
Simultaneous seeding and infection 0.5 ± 0.4E + 03 0.9 ± 0.4E + 03
Means with standard deviations of infectious particle and protein concentrations in vir
(1000 ml/CS) were calculated from 5 or more independent productions.
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fig. 4. Separation of empty from full H-1PV capsids by CsCl gradient centrifugation.
apsids were detected by either hemagglutination assay (HAU) or Capsid-ELISA (PP),
hile genome containing viral particles (GP) were quantiﬁed by Q-PCR.
ime and material as compared to simultaneous seeding and
nfection, the former approach was adopted. The culture medium
upernatant contained only 10% of the total PFUs, at relatively
ow concentration (around 107 PFU/ml). As concentrating the
upernatant was cumbersome, time consuming, and inefﬁcient,
his fraction was discarded in routine productions.
.3.2. Reproducibility of the standardized upstream process and
-1PV yields
As shown in Fig. 5, the H-1PV virion yield was  highlyeproducible over ﬁve independent productions. The particle-to-
nfectivity ratio (PP/PFU) and the proportion of genome-containing
articles (PP/GP) were also similar between these productions. The
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ig. 5. Reproducibility of H-1PV production. After production in a 10-layer CS, virus
arvests were prepared and analyzed. PFU, GP, and PP titers were determined and
re expressed relative to the number of cells in the CS at the time of infection. Values
or  5 independent productions are shown.us harvests. Concentrations in cell extracts (20 ml/CS) and medium supernatants
ratio of PFU to GP to PP was 1:7 × 102:5 × 103. It thus appeared that
on average an indicator cell had to be infected with 7 × 102 genome-
containing virions to undergo a productive infection. About 14% of
the total virions contained an encapsidated genome.
3.4. Puriﬁcation of H-1PV
3.4.1. DNase digestion and clariﬁcation of H-1PV harvests
Unprocessed virus harvests were treated with DNase to digest
non-encapsidated viral and host-cell DNA and then clariﬁed by ﬁl-
tration through a Sartolab® P20 Plus ﬁlter. Results obtained for ﬁve
individual batches showed the signiﬁcance of these steps. As mea-
sured with the human DNA Quantiﬁcation Kit, 99.8% of the host-cell
DNA was removed by DNase treatment. Yet only 37% of the total
DNA was eliminated, as determined by A260nm measurement. The
residual DNA might be protected viral genomes and/or cellular DNA
fragments smaller than the h-TERT amplicons (62 bp) used for DNA
detection. As illustrated in Table 2b, the ﬁltration step eliminated
24% of the proteins. These are likely to be host cell and/or FBS-
derived since 100% of the viral particles and more than 80% of the
infectious virions were recovered after clariﬁcation (Table 2b). In
conclusion, this ﬁrst puriﬁcation step is fast and eliminates signif-
icant amounts of foreign DNA and proteins.
3.4.2. Separation of full from empty particles
To separate full from empty H-1PV particles, two gradient
centrifugation procedures were compared. Similar results were
obtained with ﬁve individual H-1PV harvests from two  10-layer
CS cultures. After clariﬁcation, each harvest was  split into two
equal parts, one of which was  puriﬁed by two consecutive step
gradients: IOD-PBS and VIS-Ringer, the Ringer and Visipaque for-
mulations of the latter being well suited for injection into humans.
As described under Section 2, after the centrifugation two frac-
tions were collected: from the region of the original 40% VIS layer
after centrifugation: a lower band (around 46% VIS, with density
of 1.25 g/ml), and upper band (around 41% VIS, with density of
1.23 g/ml), corresponding to the full-particle and empty-particle
fractions. As shown in Fig. 6a, the mean titer of infectious par-
ticles in the full-particle fraction was 1.3 × 1010 PFU/ml, while
the GP and PP concentrations were respectively 9.2 × 1012 GP/ml
and 1.7 × 1013 PP/ml. Titers in the empty-particle fraction were
6.3 × 109 PFU/ml, 4.6 × 1012 GP/ml, and 3.9 × 1013 PP/ml. The sec-
ond half of the virus harvest was  fractionated on a continuous
Table 2b
Virus harvest yields (cell extracts) and recoveries after clariﬁcation.
Virus harvest After clariﬁcation Recovery %
PFU/ml 7.2 ± 6.4E + 09 5.8 ± 6.1E + 09 81
GP/ml 4.8 ± 2.7E + 12 6.1 ± 3.4E + 12 127
PP/ml 1.7 ± 0.8E + 13 1.9 ± 1.3E + 13 111
protein g/ml 2.1 ± 0.9E + 03 1.6 ± 0.4E + 03 76
Virus recovered from one 10-layer CS was  dissolved in 20 ml VTE and the PFU, GP and
PP  were determined. Protein concentration was quantiﬁed by colorimetric assay.
Means with standard deviations for 5 independent productions are shown. Recovery
was calculated after clariﬁcation of the virus harvest by 0.2 m ﬁltration.
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The H-1PV preparations were analyzed for protein and DNA
contamination, the presence of endotoxins, and sterility. Proteins
from different steps and gradient fractions in the puriﬁcation pro-
cess were analyzed by SDS-PAGE and revealed by silver staining.
Table 3
Effect of UV irradiation on contamination of the empty-particle fraction by infectious
virions.
Titera Empty-particle fractionb UV-inactivated empty-particle fractionc
PP/ml 1.1 ± 0.7E + 14 1.1 ± 0.7E + 14
GP/ml 1.2 ± 1.0E + 12 9.0 ± 5.1E + 10
PFU/ml 1.8 ± 3.0E + 09 1.6 ± 0.8E + 02
PP/PFU 4.6 ± 4.3E + 05 6.9 ± 4.9E + 11ig. 6. Extent of full- from empty-particle separation after density gradient centrifu
iters  of the indicated fractions are shown (means with standard deviations from 5 
sCl density gradient followed by dialysis against VTE. As shown
n Fig. 6b, the empty-particle fraction displayed a slightly higher
article concentration (1.1 × 1014 PP/ml) and still contained resid-
al infectious viruses (1.8 × 109 PFU/ml, 1.2 × 1012 GP/ml). The
nfectious particles in the full-particle fraction had a PFU titer com-
arable to that obtained after the IOD-PBS and VIS-Ringer gradient
entrifugations (1.0 × 1010 PFU/ml), while contamination by empty
articles was slightly reduced (1.4 × 1013 PP/ml). Both methods
howed good reproducibility.
.4.3. Recovery of and enrichment in infectious H-1PV particles
As shown in Fig. 7a, the IOD-PBS density gradient centrifuga-
ion led to a signiﬁcant loss of infectious particles (46%). Further
oss at the subsequent VIS-Ringer gradient step was negligible. It is
oteworthy that the combined Iodixanol gradient centrifugations
ed to elimination of more than 90% of the total protein from the
nfectious virus fraction. The IOD-PBS step resulted in a 15.4-fold
ncrease in speciﬁc activity and the VIS-Ringer step, in a further 5.9-
old increase. Hence, an overall 91-fold increase in speciﬁc activity,
o 3 × 1011 PFU/mg protein, was achieved through this puriﬁcation
rocess. On the other hand, CsCl density gradient puriﬁcation led
o a slightly higher loss of infectious particles (57%) but to more
fﬁcient protein elimination, resulting in a 227-fold increase in spe-
iﬁc activity. The resulting particle-to-infectivity ratio (PP/PFU) was
lose to 103:1 after both puriﬁcation methods.
.4.4. Recovery of empty particles
As shown in Fig. 7b, the recovery of physical particles in the
mpty-particle fraction was higher after CsCl density gradient
uriﬁcation (78% of the total PP from the clariﬁed virus harvest)
han after the IOD-PBS and VIS-Ringer density gradient centrifuga-
ions (7%).
Furthermore, the VIS-Ringer empty-particle fraction contained
 relatively high proportion of GPs (GP-to-PP ratio: 1:10) and PFU
PFU-to-PP ratio: 1:104) as compared to the CsCl empty-particle
raction (GP-to-PP ratio: 1:102; PFU-to-PP ratio: 1:105). This leads
s to recommend CsCl density gradient centrifugation for the
reparation of empty capsids. The capsid concentration of the CsCl
mpty-particle fraction was about 1.4 × 1014 PP/mg protein..4.5. H-1PV concentration by continuous VIS-Ringer gradient
entrifugation
The titer of infectious particles in virus batches obtained by
eans of the above-mentioned IOD-PBS/VIS-Ringer and CsCln in either (a) IOD-PBS and VIS-Ringer successively or (b) CsCl. The PFU, GP, and PP
endent experiments).
puriﬁcation methods was about 1 × 1010 PFU/ml. Since a higher
titer is required for some applications, we substituted the VIS-
Ringer step gradient with a continuous gradient. This alternative
method allowed full particles to concentrate in a few fractions
(Fig. 8, fractions 4–6) which were farther from the peak of empty
particles (fractions 10–12, data not shown) and concentrated up
to 3 × 1011 PFU/ml.
3.5. Inactivated empty particles
In the empty-particle fraction obtained after CsCl fractionation,
infectious virus could still be detected (PFU-to-PP ratio: 1:105). To
allow the use of empty particles as a non-infectious control, it was
necessary to develop an inactivation method that eliminates virus
infectivity without altering capsid structure. This was achieved by
UV irradiation (Table 3). While UV irradiation did not change the PP
titer, it reduced the measured GP titer by 90%. This is likely due to
interference of the DNA damage induced in the viral genomes with
their titration by Q-PCR. Importantly, UV irradiation reduced virus
infectivity by more than 7 logs, with a residual infectivity as low as
1 PFU per 7 × 1011 PP. This made it possible to use puriﬁed prepa-
rations of UV-irradiated empty particles as non-infectious controls
in preclinical studies of the oncolytic effects of H-1PV (Kiprianova
et al., 2011).
3.6. Purity of the H-1PV preparationsa PP, physical particles; GP, genome-containing particles; PFU, plaque-forming
units.
b After CsCl gradient centrifugation (see Fig. 6b).
c 254 nm, 0.5 mW/cm2, samples irradiated 4 times for 2 min at 5-min intervals.
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Fig. 7. Recovery, speciﬁc activity and particle-to-infectivity ratio in full- and empty-particle fractions. Virus harvest was clariﬁed and then puriﬁed by IOD-PBS and VIS-Ringer
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ntermediate and full-particle fractions. (b) Speciﬁc capsid titer (PP/mg), PP recover
s illustrated in Fig. 9a, the expected viral polypeptides VP1, VP2,
nd VP3 were detected. The amounts of impurities remaining after
ensity gradient fractionation were low to undetectable. The two
uriﬁcation methods were similarly effective. It is worth noting
hat the CsCl-puriﬁed empty particles were devoid of VP3, in keep-
ng with the fact that empty capsids fail to undergo VP2-to-VP3
leavage (Paradiso et al., 1984; Tattersall et al., 1976). No signiﬁ-
ant capsid protein degradation was observed after UV irradiation.
estern blot analysis conﬁrmed the identity of the VP polypeptide
ands (Fig. 9b). No ultrastructural difference between non- and UV-
rradiated capsids was observed by electron microscopy (Fig. 9c and
). Puriﬁed batches of full capsids contained less than 2.5 EU/ml,
hatever the puriﬁcation method, while empty, inactivated parti-
le batches contained less than 25 EU/ml, compatible with the use
f H-1PV preparations in animal models under the US Food and
rug Administration limit of 5 EU/kg body weight (Malyala and
ingh, 2008). All preparations proved to be sterile.
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analyzed. (a) Speciﬁc activity (PFU/mg), PFU recovery (%), and PP/PFU ratio in the
and PP/PFU ratio in the intermediate and empty-particle fractions.
4. Discussion
Oncolytic protoparvovirus research has reached the stage of
translation into clinical practice, with a ﬁrst phase I/IIa study of
H-1PV in patients with recurrent resectable malignant glioma
(Geletneky et al., 2012). This trial is expected to be followed by
further clinical studies aiming to assess efﬁcacy and to extend the
approach to other cancers such as pancreatic carcinoma or neurob-
lastoma (Lacroix et al., 2010; Li et al., 2013). These developments
rely on the availability of robust procedures for protoparvovirus
production and characterization. On the one hand, standardized
procedures are needed to generate preclinical data that can
provide proof of concept. The use of well-characterized virus
preparations and analytical methods is indeed a prerequisite to
obtaining valid, reproducible evidence of the therapeutic efﬁcacy
of oncolytic protoparvoviruses in cancerology. On the other hand,
standard operating procedures are also required for the transfer
 4 5 6 7 8 9 10
IU/mL PFU/mL
IS/Ringer fractions
 harvest was clariﬁed and then puriﬁed by density gradient centrifugation, ﬁrst in
ere determined in the clariﬁed virus harvest, after the IOD-PBS step gradient, and
zed, showing infectious H-1PV concentrations up to 3.0 × 1011 PFU/ml.
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Fig. 9. Protein composition of virus batches from successive puriﬁcation steps. Panels a, b: Protein extracts from virus samples (1 × 1010 PP) were analyzed by SDS-PAGE and
revealed by (a) silver staining or (b) immunblotting with VP antibodies. Lane 1: Virus harvest, lane 2: clariﬁed virus harvest, lanes 3–7: CsCl gradient fractions corresponding
to  full (3), intermediate full/empty (4), empty (5), UV-irradiated intermediate full/empty (6), and UV-irradiated empty (7) particles, lane 8: virus particles from the IOD-PBS
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gradient, lanes 9–11: VIS-Ringer gradient fractions corresponding to full (9) interm
icrographs showing empty-particle fractions before (c) and after (d) irradiation.
f technologies and standards to the certiﬁed facilities in charge of
roducing clinical batches and establishing their speciﬁcations.
The present paper illustrates this standardization effort. It
escribes methods currently used in our laboratory to support pre-
linical research. We  have achieved improvements at three steps
f H-1PV stock preparation: (1) reproducible, standardized, large-
cale virus production, (2) virus puriﬁcation and concentration by
lternative procedures, and (3) implementation of quality control
riteria.
.1. Reproducible, standardized, large-scale H-1PV production
We  have established a robust, standardized H-1PV production
rocess, as illustrated above for ﬁve individual virus batches and as
ummarized in Fig. 1. A virus yield of 2 × 1011 PFU with a concen-
ration of 1 × 1010 PFU/ml, compatible with preclinical and clinical
sage, was achieved with a single 10-layer CS chamber. This yield
orresponds to a productivity of about 1 × 103 infectious parti-
les per infected cell. The 10-layer system provides approximately
he same attachment surface as a 100 cm × 10 cm cell culture dish
Halder et al., 2012). Important keys to efﬁcient production are the
ood condition of producer cells (NB-324K), with a viability over full/empty (10), and empty (11) particles, M:size markers. Panels c and d: Electron
95%, a passage number below 20, no mycoplasma contamination
(Multiplexion, Germany), and the consistent quality of the FBS.
Our attempts at up-scaling H-1PV production in a roller bot-
tle system failed, even when intermittent 5% CO2 gassing and
HEPES/NaHCO3 buffering were applied (data not shown). This
highlights the importance of CO2 gassing to provide the optimal
intracellular milieu for virus production. In our hands, a simple
and efﬁcient way to achieve up-scaling was to use CS chambers,
giving recoveries of up to 1 × 1012 PFU from ﬁve 10-layer cham-
bers. Further up-scaling would be possible with 40-layer chambers,
although their handling of shaking and gassing is more cumber-
some. Further up-scaling with adherent cells would involve the
use of carriers, as described for vaccine production (Rajendran et al.,
2014). An attractive alternative would be to use suspension cell cul-
tures in wave reactors, as described for mink enteritis PV vaccine
production (Hundt et al., 2007).
4.2. Efﬁcient puriﬁcation and concentration of H-1PV
preparations
Unprocessed virus harvests contained full, empty, and
intermediate-density particles, and were contaminated by
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oth viral and host-cell DNA and proteins. They were ﬁrst DNAse
reated and then clariﬁed through a 0.2-m ﬁlter. This resulted in
limination of 37% of the host-cell DNA and unpackaged viral DNA
nd of 24% of the total protein. Residual fragments of host-cell
NA proved to be smaller than 62 bp.
H-1PV was further puriﬁed by Iodixanol or CsCl gradient cen-
rifugation. These methods were compared regarding the H-1PV
iter obtained, separation of full from empty particles, and the
resence of contaminating proteins, as measured by electron
icroscopy and Coomassie blue staining after SDS-PAGE. In a
ecent report (Halder et al., 2012), high puriﬁcation of empty versus
ull particles was achieved through three rounds of CsCI centrifu-
ation, as evidenced on electron micrographs. Yet because of CsCI
oxicity, this procedure is not recommended for standard puriﬁ-
ation of preclinical and clinical virus batches. This prompted us
o develop a two-step puriﬁcation procedure involving successive
OD-PBS and VIS-Ringer density gradient centrifugations.
The different procedures used were compared in 5 indepen-
ent experiments. Standard deviations between recovery values
easured in these experiments were large, preventing deﬁnitive
uantitative statements from being made regarding the relative
fﬁciencies of the methods compared. However, all experiments
howed the same trends, leading us to show the following gen-
ral conclusions. Our comparison of CsCl and VIS-Ringer gradient
ractions shows the respective pros and cons of these methods. On
he one hand, CsCl gradient centrifugation appears as method of
hoice for preparing empty virions for research purposes, since the
article-to-PFU ratio in the empty-particle fraction was  ten times
igher after CsCl density gradient centrifugation than after the VIS-
inger step, with a speciﬁc titer exceeding 1014 PP/mg protein.
n the other hand, the two-step Iodixanol gradient centrifugation
rocedure emerges as a better way to purify infectious particles
ecause of CsCl toxicity (a disadvantage in the case of clinical appli-
ations) and because it is less cost- and time-consuming (half a day
ersus three days for CsCl centrifugation). Furthermore, it yields
peciﬁc activity titers around 5 × 1011 PFU/mg protein. The virus
oncentration in the VIS-Ringer full-particle fraction was about
 × 1010 PFU/ml, and increased up to 3 × 1011 PFU/ml when the VIS-
inger step gradient was replaced with a continuous gradient. The
irus fractions collected from VIS-Ringer gradients were stable for
ver two years (data not shown), allowing these fractions to be
sed as virus stocks without any further buffer change. For these
arious reasons, the Iodixanol puriﬁcation procedure is routinely
sed in our laboratory to prepare stocks of infectious H-1PV. This
rocedure was also suitable for the GMP  production of the H-1PV
atches used in the recently completed phase I/IIa clinical trial
maximum total dose of 1E10 PFU/patient). However, future phase
Ib/III trials would require the further upscaling of virus puriﬁca-
ion. Centrifugation may  be a limiting step for upscaling and we
re, therefore, committed to develop alternative methods. Besides
he density gradient centrifugation methods presented here, other
irus puriﬁcation procedures validated in other systems deserve to
e tested for their applicability to the preparation of oncolytic PVs.
hromatography and chromatofocusing are of special interest for
arge-scale production (Okada et al., 2009), since empty and full
articles can be separated by chromatography, as shown for AAV
Qu et al., 2007). The use of membrane absorbers to capture the
rotoparvovirus MVM  has also been described recently (Weaver
t al., 2013).
.3. High quality of full- and empty-particle batchesGuidelines for the control of biotechnological/biological prod-
cts have been issued at the International Conference on
armonization (http://www.gmp-compliance.org/guidemgr/ﬁles/
-1-17.PDF). These guidelines specify the levels at which drugl Methods 229 (2016) 48–59
products must be characterized, including their physicochemical
properties, biological activity, immunochemical properties, quan-
tity, purity, impurities, and contaminants. In principle, the source
material, puriﬁcation steps, and formulation ensure the consis-
tent quality of a drug product. We  have quantiﬁed and speciﬁed
our H-1PV batches according to the ICH guidelines. A particular
issue addressed in the present study was the contamination of full-
particle virus stocks by empty particles. This is important because
empty particles, although non-toxic, may  affect cell physiology and
induce antiviral immune responses (Gao et al., 2014). Methods
are thus required for quantitating both genome-containing virions
and total physical viral particles. Clearing empty particles out of
full-virion batches remains a goal for the further improvement of
puriﬁcation procedures. Conversely, it is also important to obtain
empty-particle stocks that are free of infectious virions and can
be studied for their in vitro and in vivo effects in the absence of
virus infectivity. We  have achieved this by irradiating our empty-
particle batches with UV light to inactivate infectious virions. Our
procedure results in empty-particle batches containing less than
10−10% infectious virions.
4.4. Application scope of the BL-H1 monoclonal antibody
While quantitative PCR appears as a good way  to quantify full
virions, we felt the need for a more convenient method of physical
particle quantiﬁcation. We  have thus developed a “Capsid-ELISA”
using the mAb  BL-H1, which speciﬁcally recognizes assembled
H-1PV capsids. This ELISA proved to be less cumbersome, more
reliable, and also more sensitive than the hemagglutination test
classically used to detect parvoviral particles.
Besides its use in the qualitative and quantitative control of
virus stocks, mAb  BL-H1 has proved valuable for both preclinical
and clinical-trial-accompanying research. It is used as a standard to
quantify H-1PV-speciﬁc antibodies in serum from treated animals
(Grekova et al., 2011) and could be used in the future to moni-
tor seroconversion in patients. BL-H1 can also be used as capture
antibody in an ELISA detecting viremia in infected subjects and to
screen rats from animal facilities for PV infection.
4.5. Prospects
Current research in our lab aims at developing a portfolio of
modiﬁed oncolytic protoparvoviruses, vector derivatives, and pro-
toparvovirus combination treatments with enhanced anticancer
action (Li et al., 2013; Weiss et al., 2012). These develop-
ments should yield proofs of concept to be put to the clinical
test. In order to generate and evaluate these second-generation
protoparvovirus-based therapeutics, the procedures presented
here are routinely used to produce well-characterized virus stocks
and to analyze their fate in cell cultures and animal models. Though
sufﬁcient for this purpose, the present methods can certainly be
improved further. Our group is intent on continuously exploring
strategies for up-scaling protoparvovirus production and for fur-
ther enhancing the purity and titers of protoparvovirus batches.
While the methods as they stand comply with the regulatory
requirements of the ongoing ﬁrst clinical study of protopar-
voviruses in cancer patients, their further optimization should
make them precious tools for the anticipated continuation of the
clinical validation of protoparvovirus-based anticancer treatments.
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